FILTER

Refine your search with the following facets to narrow down your results.

12 Current news of Evotec

Evotec to realign Discovery Chemistry Operations

10-Jul-2013 - Evotec AG announced that it will close its Chemistry Operations in Thane, India. All chemistry efforts will now be performed at its Abingdon (UK) facility, answering to an increasing requirement to operate closer to the principal R&D laboratories of our major customers. All project work in Thane ...

Evotec India

Evotec and Shionogi Enter Fragment-based Drug Discovery Alliance

07-Oct-2010 - Evotec AG announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd., to identify small molecule modulators of various protein-protein interaction targets. Evotec will apply its proprietary and integrated fragment-based drug discovery platform, ...

drug discovery collaborations evolution Evotec +4

Evotec Signs High Throughput Screening Agreement with Active Biotech

15-Mar-2010 - Evotec AG announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Evotec will use its expertise and technologies in assay development, ...

Evotec lead discovery medicinal chemistry +1

Evotec Signs Agreement with DiscoveRx Corporation to Support High Throughput Screening Services

21-Oct-2009 - Evotec AG and DiscoveRx Corporation announced a co-marketing agreement for the screening of GPCR’s and other targets. Under the terms of the agreement, Evotec will have access to DiscoveRx’s PathHunter™ and cAMPHunter™ cell lines and proprietary EFC chemiluminescent detection technology for use ...

business development cell lines Evotec +1

Evotec to Launch its First Innovation Centre for Fragment Based Drug Discovery

24-May-2007 - Evotec AG announced the launch of its Innovation Centre for Fragment Based Drug Discovery ('FBDD'). FBDD offers an alternative approach for identifying novel, small molecule hits (fragments) for a number of biological targets including those that have proved problematic using traditional drug ...

bases evolution Evotec +8

PerkinElmer Completes Acquisition of Euroscreen Products SA And Evotec Technologies

15-Jan-2007 - PerkinElmer, Inc. reported that it has successfully completed two previously announced acquisitions that will extend its portfolio of advanced tools for cellular analysis and High Content Screening (HCS). In the fourth quarter of 2006, the Company announced its intent to acquire Euroscreen ...

cellular imaging PerkinElmer solution

PerkinElmer to Acquire Evotec Technologies

04-Dec-2006 - PerkinElmer, Inc. announced that it has signed a definitive agreement with Evotec AG to acquire its majority owned subsidiary, Evotec Technologies GmbH, in a cash transaction valued at approximately EUR 23 million. The transaction is subject to regulatory approvals and other customary closing ...

biotechnology Evotec PerkinElmer +2

ProBioGen and Evotec Technologies Announce Successful Completion of Collaboration on Automated Cell Selection Technology

01-Sep-2006 - ProBioGen AG and Evotec Technologies GmbH have announced the successful completion of their collaboration - the joint evaluation of methods and instrumentation for the selection of high producer cells. ProBioGen could show based on it's cell-based assay technology, know how and expertise in cGMP ...

cell cultures cell lines

Evotec Sells Single Molecule Detection Technology & IP Portfolio to Olympus

25-Jul-2006 - Evotec AG announced that its Tools and Technologies Division (Evotec Technologies GmbH) has sold the core of its Single Molecule Detection Technology and transferred or licensed the corresponding IP portfolio to Olympus Corporation, Tokyo, Japan. This transaction is a further step taken by Evotec ...

bases biology Evotec +3

Evotec and Roche Form Global Alliance to Jointly Discover Novel Drugs

22-Jun-2006 - Roche and Evotec AG announced that they have formed an alliance to jointly discover and develop compounds against a target for CNS diseases and other indications. Leveraging the expertise developed by Evotec on this target, and as part of their CNS drug discovery focus, Evotec and Roche will ...

CNS drugs diseases Evotec +3